Arab Press

بالشعب و للشعب
Tuesday, Feb 24, 2026

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

The US pharmaceutical giant cashing in on a pandemic that has killed 3.2m people while failing to help the world’s poor is morally indefensible, and illustrates the corrupt nature of monopoly medicine.
As the New York Times reported, Pfizer generated hundreds of millions in profits in the first quarter of 2021, thanks to its successful Covid-19 vaccine. What’s interesting about the company’s success, however, is that its vaccine is one of just two widely used that are produced on a for-profit basis – and the only one whose manufacturer is not reliant on it to stay afloat. Pfizer’s windfall this year is, in essence, a windfall for monopoly medicine.

Unlike its Western competitors Johnson & Johnson and AstraZeneca, Pfizer decided early to profit from its vaccine. That profit margin hasn’t been disclosed, but it was predicted that this would be in the high 20% range. That means that, of the $3.5 billion brought in by the vaccine this quarter, about $900m is pre-tax profit.

Unlike Moderna, a competitor that uses similar vaccine technology to Pfizer’s, Pfizer is an extraordinarily profitable company already, making $9.6 billion in profits in 2020 before the vaccine had even had a serious impact. Moderna has no other products on the market, so turning a profit on its vaccine is crucial for its operation. Not so for Pfizer.

Pfizer sells its vaccine sales at different rates. The United States, for example, pays $19.50 for each dose, while Israel has reportedly paid $30.The reason all this is morally justifiable, Pfizer has said repeatedly, is that it was never part of the US government’s Operation Warp Speed and therefore should be allowed to set its own prices.

However, this is deceptive. BioNTech, the company that actually developed the vaccine, after which Pfizer basically slapped its label on it, received a $455 million grant from the German government and got around $6 billion in purchase commitments from the US and EU. Not only that, but the Pfizer vaccine is based on mRNA technology patented by the National Institutes of Health that was funded by US taxpayers.

In a nutshell, Pfizer capitalized on a partnership with a then-obscure German biotech company that received German government grants to develop its vaccine based on US taxpayer-funded technology, and then received purchasing guarantees from rich governments that guaranteed billions of dollars in revenue. It managed to privatize all the profits while socializing all the risk in what was a textbook case of how corrupt Big Pharma is.

But the scope of this monumental corruption really shines through when you consider that this is a once-in-several-lifetimes public health emergency that has killed millions of people. Governments around the world promised a warlike response to the Covid-19 pandemic and yet it’s mostly been just business as usual.

As I mentioned in my previous piece for RT on Bill Gates, global capitalism has reinforced itself through the pandemic, with Big Pharma being no exception. Intellectual property (IP) laws, which have only been defended in multilateral institutions such as the United Nations by rich countries, are demonstrably a barrier to getting vaccine doses out – and everyone knows it.

Even US President Joe Biden said on the campaign trail in 2020 that he would suspend IP rights to make vaccines more affordable around the globe.

“Absolutely, positively. This is the only humane thing in the world to do,” Biden said. (I’m sure the fact that Pfizer was among the companies that handed over a maximum $1 million donation to Biden’s inauguration had nothing to do with his about-face…)

But not only has IP been an issue, but even the general cost and logistics of transporting the Pfizer vaccine has proven a challenge for nations, especially poorer ones, that want to receive it. Yet, somehow, the Pfizer vaccine is emerging as the predominant Covid-19 vaccine shipped by Western countries, while lower-cost, less-intensive vaccines are being discredited.

Aside from the obvious fact that China’s vaccines or Russia’s Sputnik V are being refused for consideration, are being delayed for review by other countries, or are being conspiratorially attacked by Western media, there does seem to be some kind of bias in favor of Pfizer, even among Western vaccine-makers.

Consider that Oxford University published a study on April 15 showing that the risk of portal vein thrombosis (a blood clot in the liver) appears to be 30 times higher with the mRNA vaccines made by Moderna and Pfizer (that is, the two for-profit vaccines) than with AstraZeneca’s. Consider also that the risk of cerebral vein thrombosis (a blood clot in the brain) appears to be quite similar with both AstraZeneca (five in a million) and those mRNA vaccines (four in a million).

So, while blood-clotting concerns have caused controversy and even the discontinuation of vaccines made by AstraZeneca and Johnson & Johnson, any mention of this from mRNA vaccines in the media has been pretty much nonexistent. That’s quite strange.

Also, headlines trumpet all the time how highly effective Pfizer’s vaccine is, placing huge importance on the percentage of its effectiveness without adding context. As the Vox YouTube channel masterfully explained in a video posted in March, it’s extremely difficult to compare vaccines – especially as they’re being tested in different parts and at different times.

Pfizer’s chief executive promised to ensure that poorer countries “have the same access as the rest of the world” to its vaccine. But as of last month, wealthy nations had secured more than 87% of the more than 700 million doses of Covid-19 vaccines dispensed worldwide, while poorer countries had received only 0.2%, according to the World Health Organization.

Pfizer has pledged 40 million doses to Covax, the partnership aimed at supplying vaccines to poor countries. But, as the New York Times report points out, that’s less than 2% of the 2.5 billion doses it aims to produce this year.

Now, none of this is to say that Pfizer’s vaccine is not effective and you shouldn’t take it. I received the Pfizer vaccine and will get my second dose on Friday. The best vaccine is the one you have access to. But the problem is that Pfizer’s seems to be getting too much free exposure in the media, despite the fact it's expensive, difficult to transport, and held under IP protections, making it inaccessible to most people in the world right now.

Pfizer has successfully maneuvered our corrupt system to rake in record profits with virtually no risk at all. It’s sad to say, but this happens all the time. However, right now, it’s only artificially prolonging a once-in-a-century pandemic that, I think most of us can agree, is destroying our lives. Let Pfizer’s success this year be a historic reminder of why capitalism and public health are totally incompatible.
Newsletter

Related Articles

Arab Press
0:00
0:00
Close
GCC Secretary-General Holds Talks with EU Ambassador in Riyadh
Gulf States’ AI Investment Drive Seen as Strategic Bet on Technology and U.S. Security Ties
African Union Commission Chair Meets Saudi Vice Foreign Minister to Deepen Strategic Cooperation
President El-Sisi Holds Strategic Talks with Saudi Crown Prince in Riyadh
Lucid Unveils Up to $12,000 Incentive for Air and Gravity Models in Saudi Arabia
Saudi Arabia Enters Global AI Partnership, Expanding Its Role in International Technology Governance
Saudi Arabia’s Landmark U.S. LNG Agreement Signals Major Strategic Shift
Saudi Arabia Accelerates Global Gaming Push with Billion-Dollar Deals and Expanded PIF Mandate
Saudi Arabia Reports $25.28 Billion Budget Deficit in Fourth Quarter of 2025
Alvarez & Marsal Tax Establishes Dedicated Pillar Two and Transfer Pricing Team in Saudi Arabia
United States Approves Over Fifteen Billion Dollars in Major Arms Sales to Israel and Saudi Arabia
Pre-Iftar Walks Gain Momentum as Ramadan Wellness Trend Spreads
Middle East Jackup Rig Fleet Contracts Further After Saudi Drilling Suspensions
Türkiye and Saudi Arabia Prepare to Sign Five Gigawatt Renewable Energy Deal at COP31
King Mohammed VI Congratulates Saudi Leadership on Founding Day, Reaffirming Strategic Ties
US Envoy Huckabee Clarifies Remarks on Israel After Expansionism Controversy
Saudi Arabia Introduces Limited Exceptions to Regional Headquarters Requirement for Foreign Firms
Saudi Arabia Joins Global Partnership on Artificial Intelligence, Elevating Its Role in Shaping AI Governance
Saudi Arabia and Arab States Mobilise Diplomatically After U.S. Envoy’s Israel Remarks
Cristiano Ronaldo Reaffirms His Commitment to Saudi Arabia Amid Transfer Speculation
Proposed US-Saudi Nuclear Deal Raises Questions Over Uranium Enrichment Provisions
Saudi Arabia Sends 81st Aid Flight to Gaza as Humanitarian Air Bridge Continues
Global Games Show Riyadh 2026 Positioned as Catalyst for Saudi Arabia’s Vision 2030
Saudi Arabia Eases Procurement Rules, Allowing Foreign Firms Greater Access to Government Contracts
Türkiye and Saudi Arabia Seal Two Billion Dollar Solar Energy Agreement
Saudi Crown Prince Reportedly Sends Letter to UAE Leader Over Yemen and Sudan Policies
Saudi Arabia Voices Concerns to UAE Over Sudan Conflict and Yemen Strategy
Saudi Arabia Joins Global Artificial Intelligence Alliance to Strengthen International Collaboration
Shura Island Positioned as Flagship of Saudi Arabia’s Ambitious Red Sea Tourism Drive
Saudi Arabia Rebukes Mike Huckabee Over Remarks in Tucker Carlson Interview
OpenAI CEO Sam Altman praises the rapid progress of Chinese tech companies.
Concerns Mount Over Potential Saudi Uranium Enrichment in Prospective US Nuclear Accord
Trump Directs Government to Release UFO and Alien Information
Trump Signs Global 10% Tariffs on Imports
Investability Emerges as the Defining Test of Saudi Arabia’s Next Market Phase
Saudi Arabia’s Packaging Market Accelerates as Sustainability and E-Commerce Drive Transformation
Saudi Arabia Unveils $32 Billion Push Into Theme Parks and Global Entertainment
Saudi Crude Exports to India Climb Sharply, Closing Gap With Russia
Saudi Arabia’s Halal Cosmetics Market Expands as Faith and Ethical Beauty Drive Growth
ImmunityBio Secures Saudi Partnerships to Launch Flagship Cancer Therapy
United Kingdom Denies U.S. Access to Military Base for Potential Iran Strike
Türkiye and Saudi Arabia Launch Expanded Renewable Energy Partnership
US Supreme Court Voids Trump’s Emergency Tariff Plan, Reshaping Trade Power and Fiscal Risk
Mongolian Mining Family’s HK$247 Million Stanley Home Purchase Highlights Resilient Luxury Market
UK Intensifies Efforts to Secure Saudi Investment in Next-Generation Fighter Jet Programme
Saudi Arabia Tops Middle East Green Building Rankings with Record Growth in 2025
Qatar and Saudi Arabia Each Commit One Billion Dollars to President Trump’s ‘Board of Peace’ Initiative
Ramadan 2026 Prayer Times Set as Fasting Begins in Saudi Arabia and Egypt Announces Dates
Saudi Arabia Launches Ramadan 2026 Hotel Campaign to Boost Religious and Leisure Tourism
Saudi Arabia Seeks Reroute of Greece-Bound Fibre-Optic Cable Through Syria Instead of Israel
×